Form 144 | Ardelyx(ARDX.US) Officer Proposes to Sell 232.74K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 13, $Ardelyx(ARDX.US)$ Officer MICHAEL G. RAAB intends to sell 35,000 shares of its common stock on Jun 13, with a total market value of approximately $232.74K. MICHAEL G
Ardelyx(ARDX.US) Officer Sells US$1.03 Million in Common Stock
$Ardelyx(ARDX.US)$ Officer Williams Laura A sold 145K shares of common stock on Jun 5, 2024 at an average price of $7.125 for a total value of $1.03 million.Source: Announcement What is statement of c
Ardelyx(ARDX.US) Officer Sells US$125.1K in Common Stock
$Ardelyx(ARDX.US)$ Officer Rosenbaum David P. sold 17,872 shares of common stock on Jun 3, 2024 at an average price of $7 for a total value of $125.1K.Source: Announcement What is statement of changes
Form 144 | Ardelyx(ARDX.US) Officer Proposes to Sell 1.03 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 5, $Ardelyx(ARDX.US)$ Officer Williams Laura A intends to sell 145K shares of its common stock on Jun 5, with a total market value of approximately $1.03 million. William
How Is The Market Feeling About Ardelyx?
Ardelyx's (NYSE:ARDX) short percent of float has fallen 6.07% since its last report. The company recently reported that it has 33.04 million shares sold short, which is 16.08% of all regular shares th
Ardelyx(ARDX.US) Officer Sells US$50,390.25 in Common Stock
$Ardelyx(ARDX.US)$ Officer RAAB MICHAEL sold 7,500 shares of common stock on May 29, 2024 at an average price of $6.7187 for a total value of $50,390.25.Source: Announcement What is statement of chang
Institutional Investors May Overlook Ardelyx, Inc.'s (NASDAQ:ARDX) Recent US$276m Market Cap Drop as Long-term Gains Remain Positive
Key Insights Institutions' substantial holdings in Ardelyx implies that they have significant influence over the company's share price A total of 24 investors have a majority stake in the company wi
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Express News | Ardelyx Shares Are Trading Lower After the Company Disclosed the Resignation of Its Chief Commercial Officer
Ardelyx Slips as Commercial Chief Departs
Piper Sandler Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15
Piper Sandler analyst Christopher Raymond maintains $Ardelyx(ARDX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 49.3% and
Express News | Piper Sandler Maintains Overweight on Ardelyx, Maintains $15 Price Target
Express News | Watching Ardelyx Shares; Hearing Traders Circulate Piper Note Saying Departure Of COO Is 'Not A Positive'
What Analysts Are Saying About Ardelyx Stock
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Ardelyx (NASDAQ:ARDX) in the last three months.The following table encapsulates their recent rat
Ardelyx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/24/2024 109.64% Wedbush → $15 Reiterates Outperform → Outperform 05/03/2024 95.67% Citigroup $13 → $14
Wedbush Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15
Wedbush analyst Laura Chico maintains $Ardelyx(ARDX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 44.3% and a total averag
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ardelyx (ARDX), Cogent Biosciences (COGT) and Immunocore Holdings (IMCR)
8 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA (Tenapanor), a First-In-Class Treatment for IBS-C in Adults
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
No Data